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Abstract
Regenerative medicine (RM) is an emerging interdisciplinary field of research and China has developed the research
quickly and impressed the world with numerous research findings in stem cells, tissue engineering, active
molecules and gene therapy. Important directions are induced differentiation of induced pluripotent stem and
embryo stem cells as well as somatic stem cell differentiation potential and their application in trauma, burns,
diseases of aging and nerve regeneration. The products ActivSkin and bone repair scaffolds have been approved
and are applied in the clinic, and similar products are being studied. About 10 engineered growth-factor drugs for
repair and regeneration have been approved and are used in the clinic. Gene therapy, therapeutic cloning and
xenotransplantation are some of the strategies being studied. However, China needs to develop standards,
regulations and management practices suitable for the healthy development of RM. Aspects that should be
strengthened include sound administrative systems, laws, and technical specifications and guidelines; conservation
of stem cell resources; emphasis on training and retention of talented stem cell researchers; and reasonable
allocation of resources, diversification of investment and breakthroughs in key areas. Finally, broad and deep
international cooperation is necessary.
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Background
Since 2002, major foreign media has paid much atten-
tion to the progress of Regenerative Medicine (RM) in
China included the Wall Street Journal, New Scientist
and Times, and Journal of Applied Behavioral Analysis
[1] (www.iias.nl/iiasn/29/IIASNL29_49.pdf). In 2009,
many articles were published in Nature and the subjour-
nal Nature Reviews Molecular Cell Biology [2, 3], Cell
and subjournal Cell Stem Cell [4], New England Journal
of Medicine [5], and Regenerative Medicine and Science
[6–8]. Many media has noted the significant progress in
China and interpreted China’s policies on stem cells, tis-
sue engineering and related areas. It noted that the
Chinese government has invested a large amount of
funding in RM represented by stem cell study, tissue en-
gineering and clinical translational studies and the coun-
try has made great progress. Some reports indicated that
the Chinese government will enhance investment in RM
and has been active in recruiting well-trained re-
searchers in the 21st century and that China is leading
the area in some aspects. However, China still faces
challenges in innovation, translational application, regu-
lation, governance and management.
Progress in main fields of regenerative medicine
Stem cells
Overview
Chinese researchers started to pay much attention to
stem cells during the 1980s. In China, it is prohibited to
conduct reproductive cloning, utilize a human embryo
beyond day 14, fuse human and non-human gametes
and implant research embryos into a human or animal
uterus. The government has greatly invested in stem cell
research concentrated in several key labs in Beijing and
Shanghai. In 2001, the Chinese Academy of Sciences
(CAS) established a key lab of stem cell biology, which
was followed by the establishment of a stem cell re-
search network composed of the Shanghai Life Science
Institute of CAS, Guangzhou Institutes of Biomedicine
and Health, Biology Physics Institute, Zoology Institute,
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Genetics and Development Institute and Kunming
Zoology Institute. (1) Key Laboratory of Stem Cell
Biology, Shanghai Institutes for Biological Sciences,
Chinese Academy of Sciences. Partners are Shanghai
Jiaotong University School of Medicine, Shanghai Xinhua
Hospital, Changzhou City First People’s Hospital, the
Third Hospital Affiliated to Suzhou University, established
a biomedical translational research base. The research fo-
cuses on establishing embryonic stem cell lines, isolating
tissue stem cells, studying their stemness and differenti-
ation induction, and stem cell immunology. The main
focus is on regulating the differentiation of stem cells,
aiming to solve several major problems in the clinical ap-
plication of stem cells and developing protocols to derive
inducible pluripotent stem (iPS) to further understand their
roles in disease development. (2) Guangzhou Institutes of
Biomedicine and Health, Chinese Academy of Sciences—-
South China Institute for Stem Cell Biology and Regenera-
tive Medicine, Key Laboratory of Regenerative Biology.
This is first international demonstrative base of tech-
nology collaboration. Guangdong International Tech-
nology Collaboration Demonstrative Base of Stem Cell
and Regenerative Medicine. Cooperation institutions
are Korea Stem Cell Research Center/YonSei University
College of Medicine, Faculty of Medicine, and the
Chinese University of Hong Kong. Research Areas are
chemical biology for stem cell, stem cell physiology,
therapeutic, differentiation, molecular diagnoses and
self renew the mechanism of induced pluripotent stem
cell and its clinical application. (3) The Institute of Bio-
physics, Chinese Academy of Sciences. Research areas
are biology of embryonic stem cell, pluripotent stem cells
(PSCs), the function and regulation of neural stem cells in
the mammalian brains; Institute of Zoology, Chinese
Academy of Sciences—the Research Center of Stem
Cells and Regenerative Medicine. The Chinese-French
Laboratory of Biology of Embryonic Cells of Mammalians
(LABIOCEM) combined with the French National Institute
for Agricultural Research focusing on stem cells and iPS
cells of domestic animals, the mechanisms of cloning and
therapeutic cloning, which markedly improved the effi-
ciency of animal cloning; The Institute of Genetics and
Developmental Biology of the Chinese Academy of
Sciences and Nanjing Drum Tower Hospital (the affil-
iated hospital of Nanjing University Medical School)
established the Nanjing Stem Cells and Biomaterials
Research Center, focused on stem cell 3D culture and
self-renewal regulatory network, stem cell and biomedical
materials, tissue regeneration and wound healing and
stem cell translational medicine. (4) The Kunming
Institute of Zoology, the Chinese Academy of Sciences, co-
operation with Yunnan provincial government established
the Key Laboratory of Animal Reproductive Biology fo-
cused on rhesus monkey embryonic stem cell self-renewal
mechanism with primate animal disease models, research
stem cell pharmacology, and promoting Chinese clinical
stem cell therapy. Other famous universities and institutes
have established stem cell institutes or centers with or with-
out international cooperation (Table 1). Thus, China is
close to the global advanced-research level of embryo stem
cells and other stem cells [9].
Stem cell banks
In 2007, the Ministry of Science and Technology (MST)
established 4 stem cell banks covering the north, south
and east of China. The banks support each other with
their own technological advantages and are expected to
create a platform for 3 or 4 key technologies of stem cells
(http://www.973.gov.cn/ReadItem.aspx?itemid=1141). (1)
Northern Stem Cell Bank and Parthenogenetic hESCs
Lines Technology Platform. To establish key technology
of clinical-grade human embryonic stem cells and human
parthenogenetic embryonic stem cell bank; to create their
own stem cells and collect a variety of resources; supply
stem cell materials, information, knowledge and technol-
ogy services; and support for research institutions. (2)
Southern Stem Cell Bank and Diseases Stem Cell Lines
Technology Platform. To establish disease stem cell lines
and hpESC lines, and parthenogenetic technology plat-
form in hESC lines, complete common stem cell culture
technique and operating instruction. (3) Chinese Academy
of Sciences, Stem Cell Bank and Stem Cell Gene Manipu-
lation Technology Platform. To establish, collect, identify,
store and provide stem cells and relevant technique and
materials, and improve China stem cell resources (espe-
cially human embryonic stem cells), and promote China
stem cell research and international academic exchange.
(4) Eastern China Stem Cell Bank and Clinical Grade
hESC Lines Technology Platform. To take charge of the
National Stem Cell bank websites and databases and stem
cell bank management and coordination. To establish
clinical-grade stem cell lines and non-animal ingredients
hESC lines, offer a variety of standardized stem cells, and
provide stem cell technical consultation and training. In
2002, the information network for hematopoietic stem cell
donators was released formally online. In 2010, the Minis-
try of Health (MH) planned to establish 10 hematopoietic
stem cell banks.
Basic stem cell studies
Before 2007, basic stem cell studies in China concen-
trated on bone-marrow and embryo stem cells [10].
Since then, China was gradually moving toward the top
position in basic stem cell research [11]. Liu et al. [12]
reported the first iPS cell line from rhesus monkey in
Cell Stem Cell. In 2009, Zou et al. [13] first isolated re-
productive stem cells and cultured reproductive stem
cell strains capable of long-term self-renewal. Li et al.
Cheng et al. Military Medical Research  (2016) 3:24 Page 2 of 13
[14] first cultivated a mouse by using iPS cells. This was
the first proof of the totipotency of iPS cells. This find-
ing was elected by Times as one of the Global Top 10
Biomedicine Advances. The journal believed that “this
study is a symbol of a major step forward of stem cell re-
search”. In early 2010, Esteban et al. [15] increased the
iPS induction efficiency by 10-fold by adding vitamin C.
The Proceedings of the National Academy of Science
USA published the finding the new function of the stem
cell factor receptor C-KIT and application in transla-
tional medicine [16]. Chinese researchers published their
success in creating cell lines from androgenetic haploid
embryonic stem cells, a breakthrough in embryo stem
cell research [17]. In 2013, Hou et al. [18] used a small
molecular compound to induce the reprogramming of
somatic cells into multipotent stem cells. In 2013, Cell
published a special “Spotlight on China” edition that
highlighted the rapid development of immunology study
in China and in particular, positively commented on the
immunology aspects of applying stem cells for clinical
treatment [19] (http://www.cell.com/spotlightonchina).
Therapeutic applications
The practice of stem cell clinical trials or treatment in
China dates back to bone-marrow transplantation in the
1960s, really the transplantation of stem cells in bone
marrow. China declared the legality of stem cell treatment
as a medical technique following the United Kingdom and
the United States.
For therapeutic applications, Zhu and colleagues treated
a woman who had chopsticks inserted into her brain from
the eyes, which resulted in frontal cerebral-cortex injury.
The authors cultivated the brain tissue attached to the
chopsticks and were interested in stem cell–motivated self-
repair [20]. In 2009, Sheng et al. [21] regenerated sweat
glands by using bone-marrow mesenchymal stem cells
(MSCs). This technology has been applied in more than 30
cases with follow-up for more than four years. In 2013,
umbilical-cord MSC transplantation was performed in pa-
tients with post-traumatic brain syndrome. A total of 40 pa-
tients with post-traumatic brain syndrome were
randomized to receive stem cell or control treatment.
Umbilical-cord MSC transplantation improved the neuro-
logical function of the patients. However, these results need
to be confirmed by prospective, randomized, multi-center,
large clinical studies [22]. At the website of the State Food
and Drug Administration (SFDA) (http://www.sda.gov.cn/
WS01/CL0001/) (date of search: 2013-08-01), a few stem
cell–related products have been approved for clinical trials
(Table 2).
Table 1 Main stem cell research institutes in China
Time Name Composition
2001.01 Peking University Stem Cell Research Center Peking University
2013.07 Peking University Center for Craniofacial Stem Cell
Research and Regeneration
2001.02 Union Stem Cell and Gene Engineering Institute of Hematology and Blood Diseases Hospital,
Chinese Academy of Medical Sciences and Peking
Union Medical College
2002.01 Institute of Reproductive and Stem Cell Engineering,
Central South University
Central South University
2004 National Engineering Research Center of Human
Stem Cells
2005 Key Laboratory of Human Stem Cells and Reproductive
Engineering
2003.01 Center for Stem Cell Biology and Tissue Engineering
Sun Yat-Sen University
Sun Yat-Sen University
2008.10 Med-X-Renji Hospital Clinic Stem Cell Research Center Med-X Research Institute of Shanghai Jiao Tong
University, Renji Hospital
2011.03 Center of Stem Cells and Regenerative Medicine,
Tsinghua University
Tsinghua University
2012.01 Research Center of Stem Cell and Developmental
Biology, Zhejiang University
Zhejiang University
2012.04 Sino-US Research Center of Regenerative and
Translational Medicine
Institute for Regenerative Medicine, Wake Forest
University, Key Laboratory of Neuroregeneration,
Nantong University
2012.06 Sino-US Research Center of Stem Cell Tongji University, California Institute for Regenerative
Medicine
2012.12 Southern China Center for Stem Cell and Regenerative
Medicine
Academy of Military Medical Sciences, Guangdong
Provincial Department of Science and Technology
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Before 2005, China had no stem cell therapies and ac-
tivity factor clinical trials registered at ClinicalTrials.gov
(http://www.clinicaltrials.gov/, Fig. 1) (Additional files 1
and 2). After then, Chinese scholars have been paying in-
creasing attention to this issue and the projects registered
have been increasing annually, reaching 138 in 2012. In
2013, at the time of our search (August 20, 2013), the
number of projects registered reached 28.
Comparison with research-advanced countries on stem cells
The United States maintains a leading position in stem
cell research, for a significant difference between the
United States and China (Fig. 2). The United States has
implemented strict management since 1998. The CAS,
MST and MH in China started to make laws and policies
associated with stem cells in 2003. However, China has
improved a variety of policies so far and hopes for real
enforcement. In countries such as the United Kingdom
and Sweden, collecting human embryonic stem cells for
application is relatively free but is more stringent in
other countries. In all countries, human cloning and de-
struction of human embryos are prohibited.
In the field of stem cell drug development and clin-
ical trials, before December 31, 2009, the US Food
and Drug Administration (FDA) approved 2,980 projects
on stem cell therapy. In 2009, it allowed Geron, a bio-
tech company in California, to perform the world’s
first clinical trial on human embryonic stem cells,
which was a milestone in the history of medicine (http://
www.biotech.org.cn/information/85021). Subsequently,
another clinical trial of human embryonic stem cells,
performed by Advanced Cell Technology, was approved
by the US FDA. In 2010, the United Kingdom approved
its first stem cell trial in humans. In recent years, 3 stem
cell therapeutic agents have been approved in South
Korea. A stem cell product, Prochymal (manufactured by
Osiris), was approved by Health Canada in May 2012.
This product was the first non-prescribed MSC agent ap-
proved by a developed country for treating acute graft-
versus-host disease worldwide. In addition, the Australian
Therapeutic Goods Administration approved the produc-
tion and supply of an autologous mesenchymal precursor
cell product, Mesoblast. About 3,500 clinical trials involv-
ing somatic stem cells are registered by the US National
Institutes of Health. More than 2,000 clinical trials of stem
cell therapy are ongoing. Most of these clinical trials are
phase I to II. These clinical trials were performed mainly
in the United States and Europe. In China, stem cell ther-
apy is restricted, and the hospitals need to file with the
regulatory authorities to perform studies. In 2012, the pro-
ject “Mesenchymal stem cells in myocardial infarction in-
jection”, involving one of the three stem cell drugs
improved for clinical trials in China 6 years ago, completed
its phase I clinical trials. Before this, the SFDA approved two
stem cell drugs for clinical trials: “primitive bone-marrow
MSCs” and “autologous bone-marrow MSC injection”.
For stem cell drugs, China has lagged behind other
countries in strong stem cell research capability. Because
of lack of detailed rules in laws, the stem cell market is
in chaos driven by financial interests. The chaos in the
area of stem cell therapy in China was reported in
the New England Journal of Medicine [5] and Nature
[23, 24] in 2009 and 2010. The articles indicated con-
cern about the safety of stem cell therapy in China.
The MH has implemented regulations on the clinical
application of cutting-edge therapies such as stem-cell
injections. In December 2011, the MH report of qual-
ity control in the implementation of stem cell clinical
study and application indicated that stem cell clinical
study and application activities not approved by the
MH or SFDA should be discontinued (Table 2).
A total of 35 stem cell clinical trials have been per-
formed in mainland China, 3 in Hong Kong and 22 in
Taipei. As compared with the leading countries in the
Table 2 Stem cells products approved for clinic pre-clinic trial by the SFDA
Accept No. Generic name Usage Date Unit Status
X0400586 Bone marrow mesenchymal stem cells Injection 2004.02 The foundation of the Chinese academy
of sciences institute of medicine
Approved
CSL20020071 Human recombinant stem cell factor
for injection
Injection 2003.05 The Second Military Medical University Approved
X0408234 Mesenchymal stem cells in myocardial
infarction for injection
Injection 2005.01 Beijing Yuanhefa Biotechnology Approved
X0407487 Autologous bone marrow mesenchymal
stem cells for injection
Injection 2004.12 Institute of transfusion medicine, Academy
of Military Medical Science of PLA
Approved
CSL01037 Recombinant stem cell factor for injection Injection 2001.09 Institute of transfusion medicine, Academy
of Military Medical Science of PLA
Approved
X0404120 Umbilical cord blood nuclear progenitor
cell for injection
Injection 2004.07 Institute of transfusion medicine, Academy
of Military Medical Science of PLA
Approved
X0404119 Umbilical cord blood red blood cell
precursors for injection
Injection 2004.08 Institute of transfusion medicine, Academy
of Military Medical Science of PLA
Approved
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area of stem cell research, in China, the number of stem
cell clinical trials is significantly smaller. The application
of stem cells has mainly focused on hematopoietic stem
cells and MSCs because of the type of stem cells used in
clinical trials of hematological diseases, vascular diseases
and diabetes mellitus.
Therefore, the gap between China and the United
States as well as other leading countries in stem cell re-
search is mainly characterized by innovation, regulation,
and quality control. The review procedure and laws on
stem cell clinical trials have not been established and the
long-term mechanism needs to be improved.
Tissue engineering
Construction of tissue-engineering research system in China
Tissue-engineering research in China started in the 1990s.
In 1994, the Shanghai Science and Technology Committee
established tissue-engineering research as a priority. In
1997, the topic of tissue engineering was officially
recognized by the National Natural Science Foundation of
China. In the same year, the first tissue-engineering la-
boratory, Shanghai Key Laboratory of Tissue Engineering
Research, was established. In 1998, the national “973 Pro-
gram” for basic research officially established tissue engin-
eering as one of the research topics. In 2001 and 2002, the
national “863 High-tech Research and Development Pro-
gram” consecutively funded the application research and
product development of tissue engineering. In 2001, the
Shanghai Research and Development Center of Tissue
Engineering, also known as the research and develop-
ment center of tissue engineering in the biological
field of the national “863 Program”, was established.
In June 2012, 39 representative colleges and univer-
sities in the field of tissue engineering and RM co-
operatively founded the collaborative innovation center
for tissue engineering and RM (http://www.biotech.org.cn/
news/news/show.php?id=13984, http://roll.sohu.com/
20120630/n346960283.shtml).
Fig. 1 Clinical trials about stem cells and active factors in China, United States and European countries (www.clinicaltrials.gov/). a Stem cells;
b Active factors; c Stem cells and active factors
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Fig. 2 Comparison of stem cell research policies between China and the United States and related organizations
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In 2007, the SFDA announced the requirements for
research and submission of tissue-engineered medical
products (No. [2007]762 for medical devices). Re-
quirements for the production environment of tissue-
engineered technology in technical management spe-
cification for tissue-engineered tissue transplantation
therapy (trial) were released by the MH in November
2009. At the same time, the MH issued the Management
Specification for Class III Medical Device, New
Technology for Cell Transplantation and Tissue-
Engineered Tissue Transplantation. In 2013, China com-
pleted the registration and was granted the right to vote
for International Standards Organization (ISO)/TC150/
SC7 standardization activity as an active member country
(P member) of the ISO/Technical Committee (http://
www.gov.cn/gzdt/2013-04/05/content_2370611.htm) and
Dr. Xiaobing Fu was appointed the chair of this commit-
tee in China. China was the 13th member and the first
member in developing countries in Asia. Thus, the
standardization task in the field of tissue engineering in
China would officially go to the international stage for in-
volvement in standardization activity of international rele-
vant fields (Tables 3 and 4).
Tissue-engineering studies
In 2007, the SFDA approved the first tissue-engineering
product, ActivSkin, developed by the Fourth Military
Medical University, Xi’an, which made China the second
country in the world with the technology of artificial
skin after the United States. Moreover, the country con-
tinued to develop tissue-engineered de-cellular dermal
matrix, skin containing adipose layers, skin containing
pigmentation, skin containing capillary-like network,
skin containing hair follicles and dermal equivalents. In
2010, the SFDA approved bone-repair scaffolds devel-
oped by Fuzhai Cui, in Tsinghua University. This mater-
ial has been used in 30,000 patients and was promoted
to other parts of the world. Other products include
tissue-engineered tendons, cartilage/bone, and neural
tubes, etc (Table 4). The data could be collected on the
website of the SFDA. Fundamental research or investiga-
tional use has been conducted for tissue-engineered oral
mucosa, bladder, artificial liver and kidney, heart valve
prostheses, cardiac patch, blood vessel, nerves, urethra,
testes and thyroid glands. Thus, scientists in China have
an interest in different fields and are involved in tissue-
engineered grafts to repair and regenerate tissues and
organ. In 2012, Science reviewed the development of tis-
sue engineering in China; work from Xiaosong Gu at
Nantong University, Yilin Cao at Shanghai Jiaotong
University and Fuzhai Cui at Tsinghua University were
highlighted for their outstanding contribution in this
area [8].
Comparison with other research-advanced countries
The concept of tissue engineering was formally proposed
by the US National Science Foundation in 1987. More-
over, the United States subsidized research projects for
tissue engineering as early as 1988. Institutions involved
are research institutes (National Aeronautics and Space
Administration, the US Department of Energy, NIH),
universities (Massachusetts Institute of Technology,
Harvard Medical School, Georgia Institute of Technology,
and University of California at San Diego), and enterprises
(Sandoz, Organogenesis, Advanced Tissue).
The US FDA granted marketing approval to about 10
products including tissue-engineered skin and cartilage.
In China, tissue-engineered skin has been approved,
which marked the beginning of the industry for tissue-
engineering products. The technical level of China in
tissue engineering is basically geared to international
standards, but the delay in tissue-engineered research
and translational application in China stems mainly from
regulations and product standards. With respect to tis-
sue-engineering publications, China exceeded Germany,
Japan and the United Kingdom as early as in 2000 and the
gap with these countries has widened since 2008.
Growth factors
Overview
The supplement of exogenous bioactive factors is import-
ant for accelerating wound healing and tissue regeneration.
These bioactive factors include basic or acidic fibroblast
growth factor (bFGF or aFGF), epidermal growth factor,
nerve growth factor and bone morphogenetic protein.
Table 3 Centers/key laboratories for stem cell biology and
tissue engineering
Time Unit
2001 Key laboratory for tissue engineering research, Institute
of chemistry, Chinese Academy of Sciences
2003 Center for stem cell biology and tissue engineering,
Sun Yet-Sun University
2003 Center of tissue engineering, Chinese Academy of
medical sciences
2003 Center of tissue engineering, the Fourth Military Medical
College
2005 Key laboratory for tissue engineering research, West
China Medical University and Tsinghua University
2007 Center for biomedical materials and tissue engineering,
Peking University
2008 Key laboratory for tissue engineering research, Polymer
research institute of Tianjin University
2009 Key laboratory for tissue engineering research, Institute
of basic medical sciences Academy of military medical
sciences
2011 Zhejiang Key laboratory for tissue engineering and
regenerative medicine founded by Zhejiang University
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Table 4 Tissue engineering products approved for marketing by the SFDA
Company Time Name Constitute Application Registration No.
Beijing Jieya Laifu
Biotechnology
2006 J-1 allogeneic acellular
dermal matrix
The donation of human body’s skin,
removed the host immune rejection
of all cells, while keeping intact the
original structure with the same
extracellular matrix
To repair oral mucosal defects,
soft tissue defects.
SFDA (quasi-) word No. 2000
No. 346027, and No. 2006
3460430
2010 AlloDerm The donation of human body’s skin,
removed the host immune rejection
of all cells, while keeping intact the
original structure with the same
extracellular matrix
To repair defect of human dermal SFDA (quasi-) word No. 2010
No. 3461247
Beijing Qingyuan Albert
tissue engineering
biological technology
2007 Rhino (acellular dermal
matrix medical tissue
patch)
Acellular dermal matrix derived from
donated human skin that undergoes
a multi-step proprietary process that
removes both the epidermis and the
cells that can lead to tissue rejection
To repair various causes of oral
mucosa and soft tissue defect.
Closing the wound, dental
implantation, hernia repair,
urethral
SFDA (quasi-) word 2004
No. 3460736
Chongqing Zongshen
Junhui Biotechnology
2007 Artificial skin – gene
transfection pigskin
The product performance and
composition with fresh skin tissue
taken from Bama miniature pig as
basic material, and through the
introduction of technology and
gene transfection of CTLA4Ig gene
research.
To repair burns and other trauma
wound coverage, to promote
wound healing, prevention of
microbial infection
The Food Drug Armed (quasi)
Word 2007 No. 3461287
Qidong Oriental Medicine
Research Institute
2010 Acellular dermal matrix
dressings
Pigskin as raw material, such as viral
inactivation process with acellular
prepared from a pig dermal
extracellular matrix, is a porous
three-dimensional network structure;
mainly composed of collagen.
To repair superficial II degree burn
wounds, donor site wounds, deep
cut (cut) scab wound granulation
wounds and other wounds.
SFDA (quasi-) word No. 2010
No. 3641111
Shaanxi Eyre skin Biological
Engineering
2007 Tissue engineering skin A bilayer artificial skin substitute:
epidermal layer is composed of
human epidermal cells, dermal
fibroblasts from human and
bovine collagen.
To repair deep II degree burn
wound, not more than III degree
burn wound 20 cm2 (diameter
less than 5 cm)
The Food Drug Armed (quasi)
Word 2007 No. 3461110
BiotechnologyYantai
Zhenghai
2009 Skin repair film Cattle skin tissue after treatment
prepared by a series of acellular
dermal matrix is composed
primarily of collagen
To repair various causes dermal
wound repair defects.
SFDA (quasi-) No. 2009,
No. 3460425
2009 Biofilm Cattle skin tissue processed through
a series of prepared acellular dermal
matrix is composed primarily of
collagen, collagen retains the
unique three-dimensional structure
To repair a variety of causes dura
(spinal) membrane defects
SFDA (quasi-) No. 2009,
No. 3460602
2009 Dental film The leather prepared after a series
of acellular dermal matrix, whose
main ingredient is collagen,
sterilized by radiation, one-time use
To repair various causes shallow
intraoral soft tissue defect repair
SFDA (quasi-) No. 2009,
No. 3460404
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Table 4 Tissue engineering products approved for marketing by the SFDA (Continued)
Biological Technology of
Guangdong Grandhope
2007 General thoracic surgical
repair film
Pig tissue membranes crosslinked
epoxy chemical reagents and
biochemical transformation of
materials made of surgical repair
To repair chest wall, bronchial
stump, diaphragmatic, visceral
capsular defect, etc.
SFDA (quasi-) word No. 2007,
No. 3461317
2009 Sterile biological care
record film
The pig offal film, by the addition
of antigen and a series of biochemical
treatment and viral inactivation and
made
Skin burn, burn and trauma,
skin defects
SFDA (quasi-) No. 2009,
No. 3640426
2011 Biotypes dura (spinal)
membrane patch
Pig membranous tissue as raw
material, processed into
biotechnology, should be finished
smooth side, the other side is
allowed villous or striped or
grid-like native structure
To repair hard brain (spinal)
membrane defect
SFDA (quasi-) word 2008
No. 3460637
Beijing Datsing Bio-Tech 2011 Allogeneic bone grafts Cadaveric bone usually obtained
from a bone bank
Dental implants, to repair
broken bones that have
bone loss, and repair broken
bone that has not yet healed
Fresh Armed State Drug
Administration (prospective)
ganxibaoNo.3460627 (2011)
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Some have been approved for clinical application as new
drugs and approved with good clinical effects.
New growth factors
As early as in 1991, Chinese scientists published the
first academic monograph that systematically addressed
“growth factor and wound healing”. Since 1998, they have
published results of a series of multicenter, randomized
clinical trial about growth factors accelerating wound
healing in The Lancet and other international journals
[25]. The results indicated that bFGF and other active
molecules play a key role in regulating tissue and organ
repair and regeneration. About 10 growth-factor products
have been approved by the SFDA and used in the clinic
(Table 5).
Compared with China, the United States is more cau-
tious about the clinical application of growth factors.
Only recombinant human platelet-derived growth factor
by Chiron was approved by the FDA in 1998 and is used
for debridement healing and repair of advanced diabetic
foot ulcers, severe burns, skin diseases, and bone and
teeth defects. The recombinant human keratinocyte
growth factor palifermin, by Amgen, was approved in
2004 and is used for treatment of severe oral mucositis
caused by chemoradiotherapy. Therefore, the number is
far less than that of growth factors approved in China.
Cell differentiation and dedifferentiation induced by
growth factors are a “hot” topic in RM. In 2001, Chinese
scientists published results of a series of in vivo and vitro
studies dealing with epidermal cells dedifferentiating
into epidermal stem cells in The Lancet and other inter-
national journals [26, 27], which addressed dedifferenti-
ation as a new approach to make stem cells from skin.
Particularly, the authors found that growth factors have
a significant dedifferentiation effect on cells in vivo
settings. Although the innovative theory immediately
caused controversy between Chinese and foreign scholars,
this groundbreaking thinking has great significance for the
later practice of using active factors to reprogram adult
cells into adult stem cells. These results offer direct evi-
dence that the potential of plasticity and transdifferentia-
tion of some adult tissue stem cells could lead to
differentiation into other series of cell types without devel-
opmental correlation [28].
Other: gene therapy, therapeutic cloning and
xenotransplantation
Gene therapy has an important place in neuron, cardio-
vascular and islet-cell regeneration. Self-developed recom-
binant hepatic growth factor is the first gene therapy
product for cardiovascular disease and is now in a phase
II clinical trial. In addition, pcD2/hVEGF121 gene therapy
for peripheral vascular diseases has been approved by the
SFDA for a special clinical trial, so China is the second
country conducting such research after the United States.
“Therapeutic cloning” has always been listed as a na-
tional basic research program. It is divided into upper,
middle, and lower research parts according to national
strategic planning. Drs. Guoxiang Chen (Transgenic
Research Center in Shanghai), Huizhen Sheng and Yilin
Cao (Shanghai Second Medical University) are respon-
sible for the upper, middle and lower research parts,
respectively. With cloning, cells may be induced to dif-
ferentiate into specific tissue and organs in vitro, such as
skin, cartilage, heart, liver, kidney and bladder, then these
tissues and organs are implanted into patients.
Xenotransplantation is being accepted gradually in
addition to tissue engineering and stem cell technology.
The first batch of inbred Wuzhishan mini-pigs with GT
knockout (homozygous with 2 copies of GGTA1 gene
deletion) were established by Deng and colleagues at the
institute of animal husbandry. Pigskin excipients with re-
duced immunogenicity treated by several different
means have been approved by the SFDA. In addition,
patents have been applied for α-galactosidase–treated
porcine heart valve, pericardium and ligament. Func-
tional cells and various humanized organs for human
transplantation may be obtained if the same method is
applied in large animals. The immunological rejection of
xenotransplantation would be overcome and result in
functional organs.
Conclusions
In 2012, a special edition of Science (sponsored supple-
ment for Regenerative Medicine in China) gave a com-
prehensive snapshot of the development of RM in
China, with particular emphasis on stem cells, tissue
engineering and trauma. As the core scientific journal,
Science echoed with positive comments for the achieve-
ments in China. For scientists in China, change and
challenge in RM exists. Although its achievements are
remarkable and impressed, China needs to strengthen
the following aspects: (1) Sound administrative system,
laws, technical specifications and guidelines. China has
not yet established a truly effective management system
for clinical application of somatic stem cells, and de-
tailed regulatory rules are not clear. The standards for
stem cell conservation, research, clinical trials, eligibility
criteria for hospital and medical staff performing stem cell
therapy, relevant instruments and devices remain to be
determined. In 2009, the ministry of health put stem cell
therapy into “third class medical technology”, which
Mainly due to it involved the major ethical issues, and the
security and effectiveness still need to further confirm by
the specification of clinical trials research. In March 2015,
the National Health Development Planning Commission
and the China Food and Drug Administration jointly
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Table 5 Growth factors for external using products approved for marketing by the SFDA
Company Time Products Effect Status
Zhuhai Essex
Bio-Pharmaceutical
1998 Recombinant bovine basic
fibroblast growth factor
Burn and scald wounds: including shallow
II degree and deep II degree wounds,
granulation wounds and inhalation
injuries.
* Acute wounds: bruises, contusions,
combined injuries and cuts.
* Surgical incisions: incisions of surgery,
orthopedics, gynaecology (such as lateral
episiotomy and cesarean incision),
otolaryngology, urology and
proctology.
* Chronic wounds: diabetic ulcers, vascular
ulcers, radiochemotherapy ulcers, bedsores,
fistulas, residual wounds and cervical
erosions.
* Skin grafting: skin donor site, skin grafting
site, skin flap handling.
* Other applications: after plastic surgery,
skin resurfacing, dermabrasion, nevus
removal and laser therapy wounds.
SFDA Approval
No.S10980077
1999 Recombinant bovine basic
fibroblast growth factor
Eye Drops
* Various corneal defects and punctate
keratopathy.
* Recurrent punctate keratopathy in the
shallow layer.
* Mild or moderate dry eye.
* Corneal operation and poor corneal
healing after operation.
* Geographic (or nutritional) herpes
simplex keratitis.
* Ballous keratitis.
* Corneal abrasion, mild and moderate
chemical burns.
SFDA Approval
No.S19991022
2005 Recombinant bovine basic
fibroblast growth factor
Gel
Treatment of various keratopathy, ocular
traumas and foreign body removal.
* Corneal transplantation and eye surface
reconstruction.
* Dry eye: especially dry eye due to
corneal injury.
* Cataract surgery (ECCE. Phaco etc.):
restoration of endothelium and
reduction of edema.
* Corneal refractive surgery: repair
damaged corneas before surgery,
repair damaged nerves after
surgery and treat postoperative
dry eye
SFDA Approval
No.S20050100
Beijing SL Pharmaceutical 2002 Lyophilized Recombinant
Human Basic Fibroblast
Growth Factor (rh-bFGF)
Chronic Cutaneous Ulcer and Burn
Wounds
SFDA Approval
No.S20020025
Nanhai Longtime
Pharmaceutical
2004 Recombinant Human Basic
Fibroblast Growth Factor
for External Use
Chronic Cutaneous Ulcer and Burn
Wounds
SFDA Approval
No.S20040052
Shanghai Wanxing
Bio-Pharmaceutical
2006 Lyophilized Recombinant
Human Acidic Fibroblast
Growth Factor For
External Use
Chronic Cutaneous Ulcer and Burn
Wounds
SFDA Approval
No.S20060102
Guilin pavay gene
Pharmaceutical
2002 Recombinant Human
Epidermal Growth
Factor Hydro Gel
Chronic Cutaneous Ulcer and Burn
Wounds
SFDA Approval
No.S20020111
Wuhan HITECK biological
pharmaceutical
2006 Mouse nerve growth
factor for injection
Peripheral nerve injury and peripheral
neuropathy; Brain and spinal cord
injury; Acute cerebrovascular disease,
cerebral atrophy, Parkinson’s and
Alzheimer’s disease.
SFDA Approval
No.S20060051
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issued the “stem cell clinical research management ap-
proach (trial)”, which is first normative management doc-
uments about stem cell clinical research of China. Aim is
restraint the action of stem cells in clinical research and to
safeguard the rights and interests of the subjects, promote
the healthy development of stem cell research [29]. The
implementation should be in accordance with the guide-
lines for stem cell clinical translation released by the Inter-
national Society of Stem Cell Research. Ethical norms and
legal provisions should be strictly followed to constrain
the application and clinical trials of stem cells. Emphasis
should be paid on the protection of intellectual property,
allowing healthy and orderly development of the study of
RM. (2) Emphasis on training and retention of talented
stem cell researchers. China has become an important
member in RM competition. However, some prominent
problems should be solved. Compared with international
advanced levels, in China, the scale and overall level of
stem cell and RM research still has a long way to go. The
government must strengthen and improve the ethics con-
struction and education in scientific research units, enter-
prises, hospitals to, enhance the management and
cognitive level of medical staffs engaged in stem cell re-
search. There is not much originality, especially not many
innovative ideas and research directions that can lead the
trend. China lacks worldwide influential scientists in the
area of tissue regeneration (including stem cell, tissue en-
gineering) and coordination among multi-disciplinary ex-
perts. (3) Reasonable allocation of resources and
breakthroughs. China will use the limited funds to con-
centrate on RM research in inducing stem cell differenti-
ation, synchronous repair and regeneration of multiple
impaired tissues, construction of tissue-engineered major
organs and driving tissue-engineered products from bench
to bedside. Substantial progresses and breakthroughs have
been made in further establishing and improving the rules
and laws involved in RM and construction of a RM trans-
lational base. (4) Broad and deep international cooper-
ation. China should continue to emphasize in-depth and
practical cooperation with foreign well-known univer-
sities, scientific centers and key laboratories. The con-
struction of programmed, systemic and open research
teams at the national level can avoid the waste of re-
sources and concentrate on advantages to overcome diffi-
culties. (5) Diversification of investment and other new
technologies. Stem cell technology is attracting scientists
and entrepreneurs from various countries with its huge
market potential and has tremendous business opportun-
ities for stem cell industry. Some new technologies may
bring breakthrough developments for RM, such as the ef-
fect of 3D biological printing technology on RM. Dr.
Mingyan Xu, at Hangzhou University of Electronic Sci-
ence and Technology, also the director of the research
and development team for the Chinese biomaterials 3D
printer, independently developed the first domestic bioma-
terial 3D printer. This printer has successfully printed
small proportions of cartilage tissue of human ears and
liver. This biomaterial 3D printer is characterized by a
great variety of printed biomaterials, low incidence of cell
damage, high printing precision and convenient operation.
The development of nano-intellectual materials for RM is
important. The intellectual biomaterials may induce mo-
lecular modifications of degradable materials, resulting in
the interactions between cell integrins, induction of cell
proliferation and differentiation and synthesis and assem-
bly of extracellular matrix, thereby initiating the body’s re-
generative system. For example, the new intellectual
biomaterial can have the function of signal transduction
and control the release of growth factors or drugs intelli-
gently, thus inducing the regenerative repair of tissues and
organs directly.
Finally, RM in China in the next 10 years is ex-
pected to achieve substantial progress in systemic and
effective regulation as well as a management system
for RM research, application and synchronous repair
by inducing stem cells and regenerating a variety of
impaired tissues. The construction of major organs by
tissue engineering and large-scale application of tissue-
engineered products will be completed. These achieve-
ments will bring hope to China improve healthcare and
build a healthy society [30].
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